Demand planning in pharma has never been simple. It operates at a critical convergence where science rigor meets regulation, supply chain complexity, and commercial pressure. When it works well, it protects both patients and revenue. When it falters, the consequences show up quietly at first, in expiring inventory, regional imbalances, and missed supply signals and then suddenly, in shortages.
The uncomfortable truth is this: most pharma companies do not have a demand planning problem. They have a visibility problem.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
The Gap Between Forecasts and Reality
Traditional demand planning processes are built around structured cycles, monthly forecast reviews, quarterly S&OP meetings, inventory reconciliation exercises.
Those processes are necessary. But they are not sufficient anymore.
Today’s pharma supply chains are exposed to:
- API disruptions
- Regulatory shifts across markets
- Demand volatility across regions
- Longer and less predictable lead times
In that environment, a demand forecasting is only as useful as the speed at which it can trigger action.
Yet in many organizations, the signals sit quietly inside systems:
- Finished goods nearing expiry in one region
- Excess API stock in another
- A demand uptick that hasn’t yet been reflected in production plans
The data exists.
What’s missing is the connective tissue between it.
Silent Expiries: A Symptom of Reactive Demand Planning
Expiry write-offs rarely happen overnight.
They build slowly, often visible in ERP systems months in advance. But without continuous monitoring and cross-functional alignment, those early signals don’t convert into decisions.
Demand planning teams may see the forecast.
Supply chain teams may see the inventory.
Regulatory may be assessing changes in parallel.
But unless those views are connected, expiry risk becomes a lagging indicator rather than a leading one.
By the time someone manually reconciles the data across systems, the decision window has narrowed or closed.
Why Demand Planning Must Become Proactive
Demand planning in pharma can no longer be limited to forecast accuracy metrics.
It must answer harder, more operational questions:
- Which products are approaching expiry within the next 90-day window?
- Where do we have surplus inventory that could be reallocated before write-off?
- Which SKUs are trending toward a supply-demand imbalance next quarter?
- How do API constraints affect downstream production and market supply?
These are not reporting questions. They are decision questions.
And they require more than spreadsheets and static dashboards.
They require continuous monitoring across inventory, batch data, demand outlook, and supply constraints with insights delivered to the right people before risk materializes.
From Planning Cycles to Continuous Demand Intelligence
The shift in demand planning is subtle but significant.
It moves from:
- Periodic review to Ongoing exception detection
From:
- Static forecasts to Dynamic supply-demand alignment
From:
- Retrospective reporting to Forward-looking signals
When demand planning is supported by connected intelligence, expiry risk is flagged early. Supply gaps get caught early. Decisions get made faster. Not because the process changed — but because the context was there when it mattered.
This is not about replacing planning teams. It is about equipping them with better visibility.
Where Intelligent Workflow Support Makes a Difference
One of the practical applications of this approach is 90-day expiry monitoring — a common blind spot in pharma demand planning.
Instead of waiting for manual reconciliation, systems can continuously evaluate:
- Finished goods inventory
- API and excipient stock
- Batch timelines
- Demand forecasts
And surface simple, actionable insights:
- “These SKUs are expiring within 90 days – here is the demand outlook.”
- “This region has surplus inventory that could offset a shortage elsewhere.”
- “Projected demand next quarter exceeds available supply for these products.”
When those insights are embedded directly into daily supply chain workflows, demand planning shifts from reactive correction to proactive risk management.
Demand Planning as a Strategic Lever
In a regulated industry, demand planning is not just about operational efficiency.
It protects:
- Patient access
- Compliance posture
- Revenue stability
- Brand reputation
The organizations that navigate volatility successfully are not necessarily those with the most sophisticated forecasting models. They are the ones that connect planning, inventory, supply, and regulatory insight into a single, coherent view.
The question is not whether your systems hold the data. They do.
The question is whether your demand planning process can see risk early enough to act.
Rethinking Demand Planning in Pharma
As volatility becomes the norm, demand planning must evolve from a forecasting function to a continuous intelligent demand forecasting function.
That means:
- Connecting data across ERP, QMS, MES, and planning tools
- Monitoring expiry and supply-demand gaps in real time
- Surfacing actionable signals, not just reports
If your current demand planning process still depends heavily on manual reconciliation and periodic reviews, the next expiry write-off or shortage may already be visible, just not connected.
Explore How AIssist Supports Modern Demand Planning in Pharma
From expiry and demand intelligence to API change automation and regulated workflow integration, AIssist is designed to bring connected intelligence into everyday pharma operations.
FAQs
What is demand planning?
Demand planning is the process of determining how much of a product needs to be available, where, and when — so that supply, inventory, and production stay aligned with actual market demand. In pharma, it also accounts for shelf life, batch lead times, API availability, and multi-market regulatory requirements. A miscalculation doesn’t just affect revenue. It affects whether a medication reaches a patient on time.
What is difference between demand planning and forecasting?
Demand forecasting estimates future demand — how much will we need. Demand planning decides what to do about it — what to produce, where to stock, how to respond when reality diverges from the estimate. Forecasting is an input. Planning is the process that acts on it. Many pharma organizations have accurate forecasts but lack the planning infrastructure to convert them into fast, coordinated decisions. That is where expiry risk and supply gaps tend to emerge.
What KPIs should demand planning managers track to prevent expiry write-offs?
The most operationally useful KPIs for expiry prevention are: days of supply by SKU relative to remaining shelf life, percentage of inventory within a 90-day expiry window, stock reallocation lead time versus remaining shelf life, and forecast-to-consumption variance by region. Tracking forecast accuracy alone is insufficient — a forecast can be accurate at the aggregate level while individual batches in specific markets are quietly expiring. The KPIs that matter are the ones that connect batch-level inventory data to market-level demand outlook.
How can supply chain directors reduce the risk of stockouts without inflating safety stock?
The instinct when facing stockout risk is to build more safety stock. But in pharma, excess inventory carries its own cost — expiry risk, working capital lock-up, and storage compliance overhead. The more sustainable lever is improving signal speed. When supply chain teams can see demand shifts earlier — before they become shortfalls — they have more options: adjusting production schedules, reallocating from lower-demand markets, expediting specific SKUs. Safety stock is a buffer for uncertainty. Reducing uncertainty through better demand visibility reduces the need for the buffer in the first place.
